704 444 1111

T-407 P.006/006 F-233

Appln No. 09/856,969
Filed: August 1, 2001
Page 4

REMARKS

Claims 1-6 and 10-12 stand rejected under 35 U.S.C. § 112, first paragraph, enablement. In particular, the Examiner notes that a suitable preactivation of the enterocytes necessitates that the activating cytokines comprise a combination of Interleukin- β (IL-1 β), Tumor Necrosis Factor- α (TNF- α) and Interferon- γ (TFN- γ), and the Examiner points to the specification at page 6, lines 6-10.

To overcome the enablement rejection, Applicant has amended Claim 1 to recite that the enterocytes are preactivated with a mixture of pro-inflammatory cytokines comprising IL-1 β , TNF- α and IFN- γ . Therefore, Claim 1 is now commensurate in scope with the teaching noted by the Examiner at page 6, lines 6-10 of Applicant's specification.

Accordingly, it is submitted that the claims as now presented are fully enabled by Applicant's specification. Reconsideration by the Examiner, withdrawal of the rejection and formal notification of the allowance of Claims 1-6 and 10-12 are respectfully solicited.

Respectfully submitted,

Raymond O. Linker, Jr. Registration No. 26,419

ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Charlotte Office (704) 444-1000 Fax Charlotte Office (704) 444-1111

Customer No. 000826

CLT01/4639463v1

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the US Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below.

140. (103) 872-9306 on the date shown be

March 31, 2004

ahet F. Sherrill

Date